DARPin

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

Retrieved on: 
Wednesday, April 17, 2024
Annual general meeting, Annual, KPMG, DARPin, Compensated emancipation, Molecular Partners, Therapy, CHF, Nomination, Bank statement

The Molecular Partners shareholders confirmed the approval of the annual review, the IFRS consolidated financial statements and the annual statements for the financial year 2023.

Key Points: 
  • The Molecular Partners shareholders confirmed the approval of the annual review, the IFRS consolidated financial statements and the annual statements for the financial year 2023.
  • The Board of Directors and the members of the management board were granted discharge for the financial year 2023.
  • The shareholders voted to re-elect all members of Molecular Partners’ Board of Directors for a term of office of one year.
  • The Annual General Meeting also approved all binding motions regarding compensation for both the Board of Directors and the Management Board.

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Retrieved on: 
Tuesday, March 26, 2024
Annual, Therapy, DARPin, Molecular Partners

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2024.

Key Points: 
  • ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2024.
  • The Annual General Meeting will be held on Wednesday, April 17, 2024, 9.00 CET (doors open at 8.30 CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland.

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

Molecular Partners Announces Dismissal of Class Action Lawsuit

Retrieved on: 
Friday, March 1, 2024
Complaint, Therapy, Person, Damages, Prejudice, District court, Molecular Partners, Cooley LLP, American depositary receipt, DARPin

Molecular Partners was represented by Cooley LLP in the litigation.

Key Points: 
  • Molecular Partners was represented by Cooley LLP in the litigation.
  • The original case was filed on July 12, 2022 in the U.S. District Court for the Southern District of New York.
  • On February 5, 2024, the court dismissed the amended complaint without prejudice and gave the plaintiff the opportunity to amend the complaint by February 26, 2024.
  • On February 23, 2024, plaintiff filed a stipulation of dismissal with prejudice.

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Retrieved on: 
Friday, March 1, 2024
Therapy, Molecular Partners, Conference, DARPin, Rare-earth element

Molecular Partners’ Chief Executive Officer Patrick Amstutz will also present at the 44th Annual Cowen Health Care Conference taking place in Boston, MA, and will participate in the Leerink Global Biopharma Conference taking place in Miami, FL along with other members of the Company’s leadership team.

Key Points: 
  • Molecular Partners’ Chief Executive Officer Patrick Amstutz will also present at the 44th Annual Cowen Health Care Conference taking place in Boston, MA, and will participate in the Leerink Global Biopharma Conference taking place in Miami, FL along with other members of the Company’s leadership team.
  • Please see details below:
    Cowen Health Care Conference Presentation Details:
    Novel Oncology Targets Corporate Panel Discussion:
    Leerink Global Biopharma Conference Participation Details:
    Full Year 2023 Results Release Date and Time:
    Full Year 2023 Conference Call Details:
    The full year 2023 results presentation will also be webcast live and will be made available on the Company’s website under the investors section .
  • The replay will be available for 90 days following the presentation.
  • In order to register for the full year 2023 conference call on March 15, 8:00 am ET / 1:00 pm CET, please dial the following numbers approximately 10 minutes before the start of the presentation.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Retrieved on: 
Friday, January 5, 2024
Codevelopment, Protein, Partnership, Kidney, Molecular Partners, Novartis, DARPin, RDT, Patient, Carcinoma, Therapy, DLL3, Radiation, Pharmaceutical industry

This agreement represents the first co-development deal for Molecular Partners and Orano Med.

Key Points: 
  • This agreement represents the first co-development deal for Molecular Partners and Orano Med.
  • Both companies are developing additional radioligand therapy candidates in partnership with other companies, with Molecular Partners having announced its first collaboration with Novartis in December 2021.
  • Under the terms of the co-development agreement, Molecular Partner’s previously disclosed RDT target DLL3 (delta-like ligand 3) will be included in the partnership with Orano Med.
  • DLL3 will be exclusively developed by Molecular Partners and Orano Med as a RDT target.

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Retrieved on: 
Thursday, December 14, 2023
Molecule, Conference, Therapy, DARPin, Molecular Partners

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA.

Key Points: 
  • ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA.
  • In addition, members of Molecular Partners’ leadership team will participate in upcoming investor events in Switzerland during January 2024.

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Retrieved on: 
Sunday, December 10, 2023
Cellular, Transplant, Exposition, CD70, Cytokine release syndrome, CRi, Myelodysplastic syndrome, Molecular Partners, Society, Infrared spectroscopy correlation table, ASH, DARPin, CD123, Poster, DRS, Safety, Tetra, AML, Therapy, Pharmaceutical industry

These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.

Key Points: 
  • These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.
  • “We are excited to share these initial data for MP0533, where we see antileukemic activity, already at these low doses, with a favorable safety profile.
  • We look forward to the continuation of this study and evaluating the full potential of MP0533 for patients,” said Patrick Amstutz, CEO of Molecular Partners.
  • Details of the poster presenting these results from the ongoing Phase 1/2a trial of MP0533 at the 65th ASH Annual Meeting and Exposition can be found below.

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Retrieved on: 
Tuesday, November 14, 2023
DARPin, RDT, Immune system, Senior, Tetra, Service provider, ASH, CD70, CD40, Patient, Tumor microenvironment, Immunotherapy, Neoplasm, Therapy, FAP, Exposition, Novartis, CD33, Cancer, Trial of the century, SITC, Toxic epidermal necrolysis, Partnership, AML, Society, Molecular Partners, Myelodysplastic syndrome, CD123, Cell, CD3, Medical imaging, Vaccine, Research, CONCORD

The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.

Key Points: 
  • The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.
  • This conditional activation is intended to focus immune attack more specifically against tumor cells and minimize damage to healthy cells, a major challenge for current oncology drugs and development efforts.
  • The SWITCH-DARPin platform, a versatile novel DARPin design for conditionally triggering an immune cell attack only in the presence of defined tumor antigens.
  • The portfolio of RDT candidates represent a unique delivery system for radioactive payloads to solid tumors and has significantly expanded the company’s work in oncology therapeutics.